LifeStance Health Group, Inc.
NASDAQ:LFSTMedical - Care Facilities
+$0.17 today
- Market cap
- $5.24B
- Beta
- 1.19
- P/E (TTM)
- 146.6
- EPS (TTM)
- $0.06
Volume 6.60M
Average 3.91M
LFST Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
LifeStance Health Group, Inc.NASDAQ: LFST
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables growth accelerates
Q2 FY2026 accounts receivables of $12.55M rose 15.3% year over year, ahead of the -48.7% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 2.5% of revenue in FY2025, up 2.0 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +15.3% holds above the trailing-twelve-month pace of -48.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 36.09M USD
- Year-over-year change
- +664.2%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.09M | +664.2% |
| FY2024 | 2024-12-31 | (6.4M) | +73.5% |
| FY2023 | 2023-12-31 | (24.18M) | -11.6% |
| FY2022 | 2022-12-31 | (21.66M) | +10.5% |
| FY2021 | 2021-12-31 | (24.21M) | — |
Accounts Receivables vs competitors
How LFST compares with its peers on the latest reported figures
- LFST's LTM Jun 2026 accounts receivables of $19.37M is the 6th largest of the 7 companies compared; the peer median is $146.05M.
- Its year-over-year change of -48.7% is the lowest of 6, against a peer median of +52.8%.
- Accounts receivables amounts to 1.2% of revenue for LFST, versus a peer median of 2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $363.26M | +297.2% | +7.2% | 2.0% | |
| LTM Sep 2026 | $323.92M | — | — | 11.3% | |
| LTM Sep 2026 | $204.55M | +15.1% | -4.4% | 1.3% | |
| LTM Jun 2026 | $87.55M | +41.1% | -20.2% | 3.7% | |
| LTM Sep 2026 | $70.85M | +52.8% | +21.4% | 2.1% | |
| LTM Jun 2026 | $19.37M | -48.7% | — | 1.2% | |
| LTM Mar 2026 | $2.58M | +153.0% | — | 1.2% | |
| Peer median (excluding LFST) | $146.05M | +52.8% | +1.4% | 2.0% | |
Competitors are the stored peer set for LFST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (307.2M) | (215.56M) | (186.26M) | (57.44M) | 9.66M |
| Depreciation & Amortization | 54.14M | 69.2M | 80.44M | 70.95M | 54.75M |
| Deferred Income Tax | (26.95M) | (16.73M) | (21.92M) | (958K) | 2.42M |
| Stock-Based Compensation | 259.44M | 187.43M | 99.39M | 76.17M | 74.7M |
| Change in Working Capital | 2.14M | (16.94M) | (33.72M) | (27.37M) | (40.34M) |
| Accounts Receivables | (24.21M) | (21.66M) | (24.18M) | (6.4M) | 36.09M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 623K | 7.67M | (5.61M) | 501K | (1.56M) |
| Other Working Capital | 25.73M | (2.94M) | (3.94M) | (21.47M) | (74.87M) |
| Other Non-Cash Items | 27.85M | 45.4M | 45.2M | 45.91M | 44.96M |
| Operating Cash Flow | 9.42M | 52.79M | (16.88M) | 107.26M | 146.15M |
| Capital Expenditures | (94.49M) | (79.26M) | (40.52M) | (21.57M) | (36.13M) |
| Acquisitions (Net) | (99.58M) | (60.21M) | (19.82M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (194.08M) | (139.46M) | (60.34M) | (21.57M) | (36.13M) |
| Debt Repayment | (223.77M) | 69.56M | 55.28M | (1.69M) | (7.25M) |
| Common Stock Issued | 549.91M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (904K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (12.28M) | (21.39M) | (7.86M) | (8.26M) | (8.71M) |
| Financing Cash Flow | 313.86M | 47.26M | 47.43M | (9.95M) | (15.96M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 129.2M | (39.41M) | (29.8M) | 75.75M | 94.07M |
| Free Cash Flow | (85.07M) | (26.47M) | (57.4M) | 85.69M | 110.03M |
LifeStance Health Group, Inc.
NASDAQ:LFST
Intrinsic Alpha fair value
Locked
Current Price
$13.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.